SCHEMBL12856784

SCHEMBL12856784

COc1c2cccc1Cc1cccc3c1OCCOCCOCCOCCOc1c(cccc1Cc1cccc(c1OC)C3)C2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.35
▸ SMN1; SMN2 Q16637 3/20 0.35
▸ CRHBP P24387 2/20 0.35
▸ CRHR2 Q13324 2/20 0.35
▸ HTT P42858 1/20 0.35
▸ CTNNB1 P35222 1/20 0.34
▸ WNT3A P56704 1/20 0.34
▸ CYP2A6 P11509 1/20 0.33
▸ KDM4E B2RXH2 3/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ CD69 Q07108 1/20 0.32
▸ TSHR P16473 2/20 0.31
▸ CYP2D6 P10635 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ DRD2 P14416 1/20 0.31
▸ DRD1 P21728 1/20 0.31
▸ DRD4 P21917 1/20 0.31
▸ DRD5 P21918 1/20 0.31
▸ DRD3 P35462 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15541243 0.79 KDM4E (0.43) SMN1; SMN2KDM4EALDH1A1CD69TSHR
SCHEMBL12856706 0.77 SMN1; SMN2 (0.39) LMNASMN1; SMN2CRHBPCRHR2HTT
SCHEMBL18505803 0.75 CD69 (0.36) LMNASMN1; SMN2CRHBPCRHR2HTT
SCHEMBL20438296 0.74 ELANE (0.40) CYP2A6CD69
SCHEMBL18505802 0.74 CD69 (0.36) CD69TSHRCYP2D6
SCHEMBL13129398 0.74 CD69 (0.69) LMNAKDM4EALDH1A1HSD17B10CD69
Hydroxyamine SCHEMBL11037119 0.73 CD69 (0.44) SMN1; SMN2KDM4EALDH1A1HSD17B10CD69
SCHEMBL20121198 0.72 CD69 (0.34) CD69TSHRCYP2D6
SCHEMBL14093080 0.72 CD69 (0.34) SMN1; SMN2KDM4EALDH1A1CD69
SCHEMBL12856705 0.72 SMN1; SMN2 (0.32) LMNASMN1; SMN2CRHBPCRHR2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110028676-A1 Molecular Actuators, and Methods of Use Thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2011-02-03 — — US disclosed
US-7658868-B2 Class of molecular actuators where bulk actuation mechanisms such as ion intercalation are enhanced by controllable single molecule conformational rearrangements offers promise in exhibiting large active strains at moderate stresses MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2010-02-09 — — US disclosed
US-20070215839-A1 Molecular actuators, and methods of use thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2007-09-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070215839-A1 Molecular actuators, and methods of use thereof NOD2, PIEZO1, TPR LMNA 3835/4885SMN1; SMN2 4863/4885CRHBP 1080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback